MRAの有効性の報告↓ ●https://t.co/CKzUmu4w4F ●https://t.co/wxKxyusa70 ●https://t.co/4PziqSNOL3 ※SPin-D、MiREnDa trialは有効性を示せず ※ALCHEMIST、ACHIEVEは結果待ち(negative?)
RT @Ryu04196650Ryu: @TT58852391 これとか見ると案外よさそうですよね。残念な結果っぽいですがALCHEMISTも論文化早くされて欲しいですね。
RT @Ryu04196650Ryu: @TT58852391 これとか見ると案外よさそうですよね。残念な結果っぽいですがALCHEMISTも論文化早くされて欲しいですね。
@TT58852391 これとか見ると案外よさそうですよね。残念な結果っぽいですがALCHEMISTも論文化早くされて欲しいですね。
@TEUrsbX1CWKJHnJ ツイートみて、8年ぐらい前に読んだ、透析患者にスピロノラクトン使用でCVD減るという日本発のJACCの論文思い出して検索したのでコメント失礼します。本文では、尿があんま出ないから高Kのリスクも少ないとか書いてあったようななかったような、、、小規模な試験ですが、、、 https://t.co/FdPrJfWAEo
@MaxJordan_N @kidney_boy @jbcarmody My CCU attending (the legend Steve Schulman) showed me this. Prolly doesn’t matter and likely helps https://t.co/LDN98USBkx
RT @saki108hana1210: @uni_pharmacist @toki_wo_koe 血圧や利尿目的では効果は期待できないけど、心不全の予後改善のためなら高Kを避ける管理ができるなら投与可かな思ってます。 https://t.co/Zxhfvy2Jn9
@uni_pharmacist @toki_wo_koe 血圧や利尿目的では効果は期待できないけど、心不全の予後改善のためなら高Kを避ける管理ができるなら投与可かな思ってます。 https://t.co/Zxhfvy2Jn9
@DGBassani @thebyrdlab In this instance, I’m trying to judge others’ big effect finding The condition is a high mortality one; bigger trials are ongoing. But many current patients will have died when results available. There has been much skepticism about
RT @manasib33: Several small trials have shown improved mortality in dialysis patients with spironolactone use #nephtrials https://t.co/fP…
RT @manasib33: Several small trials have shown improved mortality in dialysis patients with spironolactone use #nephtrials https://t.co/fP…
RT @manasib33: Several small trials have shown improved mortality in dialysis patients with spironolactone use #nephtrials https://t.co/fP…
RT @manasib33: Several small trials have shown improved mortality in dialysis patients with spironolactone use #nephtrials https://t.co/fP…
Several small trials have shown improved mortality in dialysis patients with spironolactone use #nephtrials https://t.co/fPELLl1jt0 https://t.co/HEiwPcaL97
@BKNoil @silentkneecap こちらも参考になると思います。https://t.co/edVlCJzqOr
@IanBHollis @brentnreed Exactly. There’s some decent data about MRA even in HD (https://t.co/dSPksSNb7j).
Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients cited by Assistant Professor of Medicine Dr. Shan Shan Chen, M.D., University of New Mexico School of Medicine #Nephrology conference https://t.co/C6
@MKIttlesonMD @KBalakumaranMD @cardiojaydoc02 @maz_hanna @IAmDrIbrahim @meverley Playing Devils advocate: https://t.co/7t3symmC3n https://t.co/hMtgeDyEJk
@JJheart_doc @gmac78 @IAmDrIbrahim @Nikhil15 @AndrewJSauer @gcfmd @EstefaniaOS @bkolskk @YevgeniyBr The effect size for mortality reduction in this RCT is pretty huge. But we've gotta see another such trial showing same, I think. https://t.co/8uoSKoa7fB
@thebyrdlab @caioqualunque @hswapnil Actually this particular review is a ton of hand waving / inappropriate animal extrapolation and very limited human data talking about BP reduction in small dialysis RCTs. I think the most solid piece of datum is the la
@ASPNeph @renalandurology How about these data that include mortality, which seems more important than surrogate outcomes https://t.co/W8dXmGU0I0
@drjosflynn How about these data that include mortality, which seems more important than surrogate outcomes https://t.co/W8dXmGU0I0
@kazemfaa @askrenal 1. unknown. Some evidence suggests benefit. Stop ACEi not exact question but testing withdrawal at low eGFR. https://t.co/uXuf6nnixx Now doubt need to watch close if you do as hyper K. Worsening kidney function common at low eGFR. Worki
RT @kidney_boy: Love that study of Spiro in dialysis patients. This one is shorter in duration but with an endpoint of reduced BP: https://…
RT @kidney_boy: Love that study of Spiro in dialysis patients. This one is shorter in duration but with an endpoint of reduced BP: https://…
RT @thebyrdlab: @pipecardio @AtulPathak31 @josegdonaire @secardiologia @SEHLELHA140_90 Rather than debate eGFR cutoff for use of various di…
RT @thebyrdlab: @pipecardio @AtulPathak31 @josegdonaire @secardiologia @SEHLELHA140_90 Rather than debate eGFR cutoff for use of various di…
RT @thebyrdlab: @pipecardio @AtulPathak31 @josegdonaire @secardiologia @SEHLELHA140_90 Rather than debate eGFR cutoff for use of various di…
Love that study of Spiro in dialysis patients. This one is shorter in duration but with an endpoint of reduced BP: https://t.co/MAh8yahU80
@pipecardio @AtulPathak31 @josegdonaire @secardiologia @SEHLELHA140_90 Rather than debate eGFR cutoff for use of various diuretics since I think it's not so clear, I'll just share things I find interesting: RCT of spironolactone in dialysis patients: http
@methodsmanmd https://t.co/EcDOfa3VVR RCT of spironolactone vs placebo in dialysis. Pts in treatment arm had longer dialysis vintage than control at randomization (and lived longer on treatment).
#EUROPD2017. Do we underuse spironolactone in #dialysis? https://t.co/TMTs4t0j4G
Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. https://t.co/WbFQ0WfYLI
@edgarvlermamd @kidney_boy oops - meant to link this in first tweet: http://t.co/oOI677Atn2 (+ve RCT but weak methods)
Spirinolactone may ⬇️ risk of both CV/ Cerebrovascular morbidity & death among HD patients http://t.co/dBR5EX7Aa4 http://t.co/UYm9dqweNz
Spirinolactone may ⬇️ risk of both CV/ Cerebrovascular morbidity & death among HD patients http://t.co/dBR5EX7Aa4 http://t.co/UYm9dqweNz
Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.http://t.co/yICEboi8Ra
.@Rx_Ed spironolactone reduces mortality in dialysis. http://t.co/zMKpA4ihBn
.@Rx_Ed spironolactone reduces mortality in dialysis. http://t.co/zMKpA4ihBn
.@Rx_Ed spironolactone reduces mortality in dialysis. http://t.co/zMKpA4ihBn
Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in HD Patients http://t.co/VgPvhrLcS7 potential 4 #NephJC
Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in HD Patients http://t.co/VgPvhrLcS7 potential 4 #NephJC
では、血液透析患者に投与したらどうかと言うとabstractしか読めていないので詳細は分かりませんが、血管系のイベントによる死亡も入院も減少されることが報告されています。http://t.co/2jEizJ5lrK もちろんこれだけでは早計だと思いますが、興味深い結果です。
では、血液透析患者に投与したらどうかと言うとabstractしか読めていないので詳細は分かりませんが、血管系のイベントによる死亡も入院も減少されることが報告されています。http://t.co/2jEizJ5lrK もちろんこれだけでは早計だと思いますが、興味深い結果です。
Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients http://t.co/bs8jU3Paya
Spironolactone improves hard outcomes in dialysis patients. Another +ve RCT! But small n;only 3 had hyperK http://t.co/KGJvphy8kk
Aldactone reduces longterm CV mortality in patients on HD http://t.co/DYSIAI3Z9V
Spironolactone reduces cardio- and cerebrovascular morbidity and mortality in hemodialysis patients http://t.co/2mlVVHfqak]
総死亡をプライマリに設定すべきだったおしい試験http://t.co/2mlVVHfqak
単純なオープンラベルであればなおさら…。http://t.co/2mlVVHfqak
果はなかなかインパクトがありまが、盲検化について抄録には具体的な記載がなく、たとえばPROBE法であれば入院のアウトカムは妥当とは言えません。http://t.co/2mlVVHfqak
日本のスタディですね。フルテキスト読みたいhttp://t.co/2mlVVHfqak
Spironolactone reduces cardio- and cerebrovascular morbidity and mortality in hemodialysis patients http://t.co/2mlVVHfqak]
【日本人透析例に対する低用量スピロノラクトン——、心血管系死亡・入院を有意に減少。総死亡も同様 [6.4% vs 19.7%]:309例無作為化 3年間追跡】 JACC http://t.co/mvLAfXpIa2 1市中病院。5クリニックによる研究です!JACC!
【日本人透析例に対する低用量スピロノラクトン——、心血管系死亡・入院を有意に減少。総死亡も同様 [6.4% vs 19.7%]:309例無作為化 3年間追跡】 JACC http://t.co/mvLAfXpIa2 1市中病院。5クリニックによる研究です!JACC!
Aldactone reduces overall mortality in HD patients http://t.co/STBDFiHljU